| Name | Title | Contact Details |
|---|
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Concord is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our dedication to small, one- or two-dentist practices sets us apart from large, impersonal dental management companies. You’ll never see Cherry Tree Dental’s name on the building or ten doctors at one office. We value established, family practices, hi...
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
The Hydropothecary is a licensed producer and distributor of medical marijuana under Health Canada`s Access to Cannabis for Medical Purposes Regulations (ACMPR). We are committed to medical excellence and achieve this through our growing techniques, process control, quality assurance testing, robust research and development, and by offering an exceptional customer service experience. We are proud of our company`s remarkable growth thus far and look forward to our continued expansion with the construction of a new greenhouse which will boast an additional 250,000 sq/ft in 2018. We are constantly seeking skilled, energetic and highly focused p-professionals who would like the opportunity to be a part of our team and of an exciting industry that is constantly evolving.